5月13日夜盘，生物制药公司伊克力西斯（Exelixis Inc，股票代码：EXEL）股价大涨6.36%，引发市场关注。这一显著涨幅主要归因于公司发布的强劲季度财报，其业绩表现远超分析师预期。
根据公司公布的财报，截至3月31日的季度调整后每股收益（EPS）达到0.55美元，大幅超过分析师平均预期的0.36美元。公司营收同比增长30.6%，达到5.5545亿美元，同样高于分析师预期的4.9818亿美元。此外，伊克力西斯本季度净收入为1.5962亿美元，展现出强劲的盈利能力。
值得注意的是，华尔街分析师对伊克力西斯保持积极态度。目前，分析师对该公司股票的平均评级为"买入"，其中11个评级为"强烈买入"或"买入"，9个为"持有"，没有"卖出"或"强烈卖出"评级。分析师给出的12个月目标价中位数为39.00美元，显示出对公司未来发展的信心。伊克力西斯作为一家专注于癌症治疗的生物制药公司，其核心产品cabozantinib在肾癌、肝癌等领域的应用前景广阔，这可能是支撑其股价上涨的长期因素之一。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.